In this Q&A episode of our pediatric neurology series, we answer listener questions about some of the most rapidly evolving areas in neurology and genetics. The discussion begins with the relationship between child abuse evaluations and Brief Resolved Unexplained Events (BRUE), including important considerations when assessing infants with unexplained symptoms.

Host Paul Wirkus, MD, FAAP and guest Josh Bonkowsky, MD then explore the neurologic basis of developmental disorders and the growing role of advanced diagnostics such as genome sequencing and MRI. Our guests discuss how these tools can provide valuable insights into underlying conditions and increasingly influence treatment decisions and long-term care planning.

The conversation also examines the complex relationship between genes, brain development, and the symptoms children experience. As genetic testing becomes more widely available, we consider the promise of gene therapy, the emerging field of precision medicine, and realistic timelines for translating these advances into everyday clinical practice. Finally, we discuss the benefits of obtaining a genetic diagnosis-even when a cure is not yet available-including connecting families with resources, reducing isolation, informing future care decisions, and the potential expansion of newborn screening programs as genetic therapies continue to develop.

Have a question? Email [email protected]. Listener questions will be answered in episode four. 

For more information about available credit, visit vCurb.com.

ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Colorado Medical Society through the joint providership of Kansas Chapter, American Academy of Pediatrics and Utah Chapter, AAP.  Kansas Chapter, American Academy of Pediatrics is accredited by the Colorado Medical Society to provide continuing medical education for physicians.
 
AMA Credit Designation Statement

Kansas Chapter, American Academy of Pediatrics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.